Gilead keeps Maryland order blocking unauthorized foreign-market drug imports
Differences in labeling and quality controls mattered to the trademark analysis even though the domestic and foreign drugs used the same formulation.
The Fourth Circuit kept a Maryland injunction in force that restricts several companies from advertising, selling or facilitating the sale in the United States of foreign-market Gilead products. The August 13 decision, amended August 18, addresses how federal trademark law applies when unauthorized imports are made by the trademark owner but sold with different labeling and outside its domestic distribution controls. The panel reviewed a preliminary order, leaving the underlying claims for further proceedings.
The dispute began after a Maryland patient received a Turkish-market version of a Gilead drug through an import arrangement. Gilead sued, alleging trademark infringement and unfair competition under the Lanham Act, among other claims. The district court granted preliminary relief against various businesses and an executive involved in sourcing, arranging or processing the transactions. The appellants argued in part that the imported medicines were genuine because Gilead made them and their formulations matched domestic versions.
Judge G. Steven Agee’s opinion distinguished physical composition from the features consumers expect a mark to guarantee. The court pointed to differences in warning labels, prescribing information, packaging and identification. It also noted that the products moved outside Gilead’s controls for domestic shipments, including temperature monitoring and traceability. The panel held that the record supported treating the imports as materially different for trademark purposes and finding a likelihood of confusion. Its analysis concerned trademark protection and did not depend on finding a violation of FDA regulations.
The court also analyzed preliminary contributory liability for service providers. Under Inwood Laboratories v. Ives Laboratories, one route to liability is knowingly continuing to supply services to an identified party engaging in infringement. The court ruled that a prior notice from the trademark owner is unnecessary and declined to treat direct control of the mechanism of infringement as a separate element. It found the record sufficient to sustain the district court’s assessment of the claims against the companies providing relevant administrative services.
The decision also addresses the limits of the first-sale doctrine. Under ordinary circumstances, resale of a genuinely trademarked product does not itself imply infringement. Here, the panel explained that material differences can change what a purchaser receives under the mark, even when the original manufacturer made the item. The importance of labeling and established quality controls depended on what consumers would reasonably expect the trademarked product to include.
The panel separately considered whether the district judge properly weighed the public interest, including the appellants’ argument about access to lower-priced prescription drugs. It concluded the public-interest comparison could account for the material differences identified in the record. That analysis was tied to the specific interim order, and the ruling did not determine the value of competing drug-distribution policies generally.
Judges Pamela Harris and Senior Judge Barbara Keenan joined Agee without separate writings. The panel reached the appellate merits of the preliminary-injunction decision, including the likelihood of success under federal trademark law, and affirmed. The ruling sets a precedential standard for analyzing the claims while the injunction remains preliminary.